Manmeet Ahluwalia MD, FACP, MBA
Deputy Director, Chief of Medical Oncology, and Chief Scientific Officer, Miami Cancer Institute, Miami, FloridaDr. Manmeet Ahluwalia is the Chief Scientific Officer, Chief of Medical Oncology, and Deputy Director and Fernandez Family Endowed Chair in Cancer Research at Baptist Health Miami Cancer Institute. Previously, he was the Dean and Diane Miller Family Endowed Chair in Neuro-Oncology in the Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center (BBTC), Cleveland Clinic, Ohio, where he subspecialized in treatment of patients with brain tumors and brain metastases. He was also a Professor in the Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
A neuro-oncologist, Dr. Ahluwalia's research focuses on the development of new therapies for patients with brain tumors and brain metastases. He is currently leading several clinical trials involving new targeted therapies as well as immunotherapeutic approaches. His research has been presented nationally and internationally and has resulted in over 175 editorials, peer-reviewed manuscripts, and book chapters.
Recent Contributions to PracticeUpdate:
- Ruxolitinib in Newly Diagnosed High-Grade Gliomas (CRUX)
- Ibrutinib With Temozolomide and Radiation in Newly Diagnosed Glioblastoma
- Low-Intensity Focused Ultrasound for Liquid Biopsy in Glioblastoma
- SurVaxM for Newly Diagnosed Glioblastoma
- Ruxolitinib With Temozolomide and Radiation for High-Grade Glioma
- Genomic Analysis of Patients With NSCLC-Associated Brain Metastases
- Tumor Genomic and Gut Microbiota Association With Clinical Outcomes in Newly Diagnosed Glioblastoma Treated With Atezolizumab, Temozolomide, and Radiation
- Veliparib Plus Temozolomide for MGMT Promoter Hypermethylated Glioblastoma
- Proton Craniospinal Irradiation With Photon Involved-Field Radiotherapy for Solid Tumor Leptomeningeal Metastasis
- Intramuscular INO-5401 + INO-9012 With Cemiplimab in Newly Diagnosed Glioblastoma